latanoprost and Blepharoptosis

To report, with supporting photo-documentation, cases of latanoprost-induced prostaglandin-associated periorbitopathy (PAP).. Retrospective small case series with three cases. Chart review with photo-documentation of clinical features of prostaglandin-associated periorbitopathy resulting from latanoprost use. Patients developed involution of dermatochalasia, blepharoptosis, deepening of orbital sulci, and flattening of lower eyelid bags after a mean usage period of 6 years (3 to 8 years).. Latanoprost can cause PAP, although it has a lower risk and longer latency of onset than those with bimatoprost and travoprost. Clinicians should be aware of this side effect and monitor for signs periodically. Chronic unilateral prostaglandin use may cause unfavorable asymmetry in the appearance of the periorbital area.

Topics: Aged; Antihypertensive Agents; Blepharoptosis; Cutis Laxa; Eyelid Diseases; Female; Glaucoma, Open-Angle; Humans; Latanoprost; Male; Middle Aged; Orbital Diseases; Prostaglandins F, Synthetic; Retrospective Studies

To report a case of lash ptosis caused by latanoprost.. Observational case report.. Retrospective chart review.. A 61-year-old, ocular hypertensive man who was using latanoprost OU presented with trichomegaly and bilateral lash ptosis. The lash ptosis had not resolved 6 months after stopping latanoprost, and anterior lamellar repositions were performed. At last follow-up, 8 months after surgery, the lids were in a normal position, but the trichomegaly had reduced only slightly.. Lash ptosis should be considered as a possible complication of latanoprost therapy.

Topics: Antihypertensive Agents; Blepharoptosis; Eyelashes; Humans; Hypertrichosis; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic